

# Angelica Corral Garcia Heras

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/698/angelica-corral-garcia-heras-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37  
papers

869  
citations

19  
h-index

28  
g-index

37  
ext. papers

952  
ext. citations

6.1  
avg, IF

3.29  
L-index

#	Paper	IF	Citations
37	PCL/collagen blends prepared by solution blow spinning as potential materials for skin regeneration. <i>Journal of Applied Polymer Science</i> , <b>2021</b> , 138, 50493	2.9	2
36	Fibrous nanocomposites based on EVA40 filled with Cu nanoparticles and their potential antibacterial action. <i>Materials Today Communications</i> , <b>2019</b> , 20, 100581	2.5	7
35	Preparation and Characterization of Antimicrobial Films Based on LDPE/Ag Nanoparticles with Potential Uses in Food and Health Industries. <i>Nanomaterials</i> , <b>2018</b> , 8,	5.4	24
34	Photoswitching-Enabled Contrast Enhancement in Light Sheet Fluorescence Microscopy. <i>ACS Photonics</i> , <b>2017</b> , 4, 424-428	6.3	7
33	Short communication high risk of endothelial dysfunction in HIV individuals may result from deregulation of circulating endothelial cells and endothelial progenitor cells. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 656-9	1.6	16
32	Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. <i>Journal of Clinical Virology</i> , <b>2011</b> , 50, 148-52	14.5	9
31	High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. <i>Aids</i> , <b>2010</b> , 24, 467-9	3.5	28
30	Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 967-72	1.6	14
29	Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 4153-8	5.9	6
28	Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. <i>Journal of Clinical Microbiology</i> , <b>2009</b> , 47, 1031-6	9.7	58
27	Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 1782-5	11.6	16
26	Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. <i>Aids</i> , <b>2008</b> , 22, 611-6	3.5	33
25	Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. <i>Aids</i> , <b>2008</b> , 22, 311-3	3.5	6
24	Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 1040-6	19.7	39
23	Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , <b>2007</b> , 23, 879-85	1.6	31
22	Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 1409-10	5.1	28
21	Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 885-8	5.1	52

20	High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. <i>Aids</i> , <b>2007</b> , 21, 2503-11	3.5	58
19	Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. <i>Aids</i> , <b>2006</b> , 20, 1071-4	3.5	24
18	Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, 291-5	11.6	104
17	Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. <i>Aids</i> , <b>2005</b> , 19, 2036-8	3.5	40
16	Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use. <i>AIDS Patient Care and STDs</i> , <b>2005</b> , 19, 67-9	5.8	4
15	Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection. <i>Journal of Medical Virology</i> , <b>2005</b> , 76, 1-6	19.7	7
14	Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 1350-4	11.6	41
13	Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 227-32	11.6	25
12	Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 1231-8	11.6	28
11	Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. <i>Journal of Virological Methods</i> , <b>2004</b> , 121, 115-8	2.6	20
10	Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. <i>Aids</i> , <b>2004</b> , 18, 689-90	3.5	4
9	Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. <i>Aids</i> , <b>2004</b> , 18, 2091-4	3.5	15
8	Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. <i>Aids</i> , <b>2004</b> , 18, 2094-6	3.5	33
7	Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. <i>AIDS Research and Human Retroviruses</i> , <b>2003</b> , 19, 457-9	1.6	11
6	Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. <i>Journal of Clinical Microbiology</i> , <b>2003</b> , 41, 1245-7	9.7	32
5	Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients. <i>Aids</i> , <b>2003</b> , 17, 919-21	3.5	3
4	Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 1288-9	11.6	3
3	Prevalence of G333D/E in naive and pretreated HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , <b>2002</b> , 18, 857-60	1.6	16

2	Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. <i>Aids</i> , <b>2002</b> , 16, 1830-2	3-5	19
1	Prevalence of Novel Lamivudine-Resistant Genotypes (E44D/A, V118I) in Naive and Pretreated HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2000</b> , 25, 95-96	3-1	6